Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.
In a win for Johnson & Johnson, its Actelion unit has settled an infringement lawsuit after generic drug maker Laurus conceded that a patent for a pulmonary hypertension drug was valid.
Allergan should not be permitted to immediately appeal against a recent ruling which requires it to face allegations that it monopolised the pricing of dementia drugs, according to a New York-based patent attorney.
Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.
The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.
New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.
The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.